Levofloxacin Hemihydrate | CAS# 138199-71-0 | Fluoroquinolone Antibiotic

MedKoo Cat#: 564089 | Name: Levofloxacin Hemihydrate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levofloxacin Hemihydrate is a broad-spectrum, third-generation fluoroquinolone antibiotic, inhibiting DNA gyrase (bacterial topoisomerase II).

Chemical Structure

Levofloxacin Hemihydrate

CAS#138199-71-0 (Hemihydrate)

Theoretical Analysis

MedKoo Cat#: 564089

Name: Levofloxacin Hemihydrate

CAS#: 138199-71-0 (Hemihydrate)

Chemical Formula: C36H42F2N6O9

Exact Mass: 740.2981

Molecular Weight: 740.76

Elemental Analysis: C, 58.37; H, 5.72; F, 5.13; N, 11.35; O, 19.44

Price and Availability

Size	Price	Availability
5g	USD 250.00	2 Weeks
10g	USD 400.00	2 Weeks
25g	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

100986-85-4 138199-71-0 (Hemihydrate) 177325-13-2 (HCl)

Synonym

RWJ 25213; RWJ-25213; RWJ25213; Levofloxacin Hydrate; Levofloxacin Hemihydrate

IUPAC/Chemical Name

(S)-9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hemihydrate

InChi Key

SUIQUYDRLGGZOL-RCWTXCDDSA-N

InChi Code

InChI=1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1

SMILES Code

O=C(C1=CN2C3=C(C=C(F)C(N4CCN(C)CC4)=C3OC[C@@H]2C)C1=O)O.[H]O[H].O=C(C5=CN6C7=C(C=C(F)C(N8CCN(C)CC8)=C7OC[C@@H]6C)C5=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Levofloxacin hydrate (Levofloxacin hemihydrate) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrate inhibits the DNA gyrase and topoisomerase IV.

In vitro activity:

Levofloxacin exhibited twofold greater inhibitory and bactericidal activities than ofloxacin against either extracellular or intracellular tubercle bacilli. Reference: Antimicrob Agents Chemother. 1994 May;38(5):1161-4. https://pubmed.ncbi.nlm.nih.gov/8067756/

In vivo activity:

This study investigated the toxic effect of levofloxacin (LVFX), a quinolone antibacterial agent, on cartilage by examining aspects of its in vivo toxicokinetics and effect on the function of cultured chondrocytes of the femoral articular cartilage from juvenile New Zealand White rabbits. Repeated administration of LVFX (100 mg/kg) orally for 7 days induced focal necrosis and superficial erosion in the articular cartilage of the femoral condyle, but 30 mg/kg did not. Reference: Antimicrob Agents Chemother. 1995 Sep;39(9):1979-83. https://pubmed.ncbi.nlm.nih.gov/8540702/

	Solvent	mg/mL	mM
Solubility
	DMSO	41.2	27.79
	Ethanol	10.0	27.00
	Water	27.5	74.25

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 740.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother. 1994 May;38(5):1161-4. doi: 10.1128/AAC.38.5.1161. PMID: 8067756; PMCID: PMC188169. 2. Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, Rosenthale ME. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860-6. doi: 10.1128/AAC.36.4.860. Erratum in: Antimicrob Agents Chemother 1992 Aug;36(8):1797. PMID: 1503449; PMCID: PMC189464. 3. Kato M, Takada S, Ogawara S, Takayama S. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995 Sep;39(9):1979-83. doi: 10.1128/AAC.39.9.1979. PMID: 8540702; PMCID: PMC162867. 4. JI B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4. doi: 10.1128/AAC.39.6.1341. PMID: 7574527; PMCID: PMC162738.

In vitro protocol:

In vivo protocol:

1. Kato M, Takada S, Ogawara S, Takayama S. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995 Sep;39(9):1979-83. doi: 10.1128/AAC.39.9.1979. PMID: 8540702; PMCID: PMC162867. 2. JI B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4. doi: 10.1128/AAC.39.6.1341. PMID: 7574527; PMCID: PMC162738.

1: Hasan AA, Sabry SA, Abdallah MH, El-Damasy DA. Formulation and in vitro characterization of poly(dl-lactide-co-glycolide)/Eudragit RLPO or RS30D nanoparticles as an oral carrier of levofloxacin hemihydrate. Pharm Dev Technol. 2016 Sep;21(6):655-63. doi: 10.3109/10837450.2015.1041044. Epub 2015 Apr 27. PubMed PMID: 25915180. 2: El-Zahaby SA, Kassem AA, El-Kamel AH. Formulation and in vitro evaluation of size expanding gastro-retentive systems of levofloxacin hemihydrate. Int J Pharm. 2014 Apr 10;464(1-2):10-8. doi: 10.1016/j.ijpharm.2014.01.024. Epub 2014 Jan 26. PubMed PMID: 24472642. 3: Gorman EM, Samas B, Munson EJ. Understanding the dehydration of levofloxacin hemihydrate. J Pharm Sci. 2012 Sep;101(9):3319-30. doi: 10.1002/jps.23200. Epub 2012 May 18. PubMed PMID: 22610517. 4: Shirkhedkar AA, Surana SJ. Quantitative determination of levofloxacin hemihydrate in bulk and tablets by UV-spectrophotometry and first order derivative methods. Pak J Pharm Sci. 2009 Jul;22(3):301-2. PubMed PMID: 19553178. 5: Chepurwar SB, Shirkhedkar AA, Bari SB, Fursule RA, Surana SJ. Validated HPTLC method for simultaneous estimation of levofloxacin hemihydrate and ornidazole in pharmaceutical dosage form. J Chromatogr Sci. 2007 Sep;45(8):531-6. PubMed PMID: 18019564.